Shahla Romal

Shahla Romal

Auto-generated profile, based on publicly available information

Shahla Romal

Department of Biochemistry Erasmus University Medical Center Rotterdam Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in eLife
Verified
Journal Article
Open access
ECElisa De Crignis
Elisa De Crignis
THTanvir Hossain
Tanvir Hossain
SRShahla Romal
Shahla Romal
FCFabrizia Carofiglio
Fabrizia Carofiglio
PMPanagiotis Moulos
Panagiotis Moulos
TMTokameh Mahmoudi
Tokameh Mahmoudi
The molecular events that drive hepatitis B virus (HBV)-mediated transformation and tumorigenesis have remained largely unclear, due to the absence of a relevant primary model system. Here we propose the use of human liver organoids as a platform for modeling HBV infection and related tumorigenesis. We first describe a primary ex vivo HBV-infection model derived from healthy donor liver organoids after challenge with recombinant virus or HBV-infected patient serum. HBV-infected organoids produced covalently closed circular DNA (cccDNA) and HBV early antigen (HBeAg), expressed intracellular HBV RNA and proteins, and produced infectious HBV. This ex vivo HBV-infected primary differentiated hepatocyte organoid platform was amenable to drug screening for both anti-HBV activity and drug-induced toxicity. We also studied HBV replication in transgenically modified organoids; liver organoids exogenously overexpressing the HBV receptor sodium taurocholate co-transporting polypeptide (NTCP) after lentiviral transduction were not more susceptible to HBV, suggesting the necessity for additional host factors for efficient infection. We also generated transgenic organoids harboring integrated HBV, representing a long-term culture system also suitable for viral production and the study of HBV transcription. Finally, we generated HBV-infected patient-derived liver organoids from non-tumor cirrhotic tissue of explants from liver transplant patients. Interestingly, transcriptomic analysis of patient-derived liver organoids indicated the presence of an aberrant early cancer gene signature, which clustered with the hepatocellular carcinoma (HCC) cohort on The Cancer Genome Atlas Liver Hepatocellular Carcinoma dataset and away from healthy liver tissue, and may provide invaluable novel biomarkers for the development of HCC and surveillance in HBV-infected patients.

27 March 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
RJRobert T. Jones
Robert T. Jones
MSMathijs Scholtes
Mathijs Scholtes
AGAndrew Goodspeed
Andrew Goodspeed
MAMaryam Akbarzadeh
Maryam Akbarzadeh
SMSaswat Mohapatra
Saswat Mohapatra
JCJames Costello
James Costello
There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which is used in primary and metastatic settings in many cancer types. In bladder cancer, platinum-based chemotherapy leads to better outcomes in a subset of patients when used in the neoadjuvant setting or in combination with immunotherapy for advanced disease. Despite such promising results, extending the benefits of platinum drugs to a greater number of patients is highly desirable. Using the multiomic assessment of cisplatin-responsive and -resistant human bladder cancer cell lines and whole-genome CRISPR screens, we identified puromycin-sensitive aminopeptidase (NPEPPS) as a driver of cisplatin resistance. NPEPPS depletion sensitized resistant bladder cancer cells to cisplatin in vitro and in vivo. Conversely, overexpression of NPEPPS in sensitive cells increased cisplatin resistance. NPEPPS affected treatment response by regulating intracellular cisplatin concentrations. Patient-derived organoids (PDO) generated from bladder cancer samples before and after cisplatin-based treatment, and from patients who did not receive cisplatin, were evaluated for sensitivity to cisplatin, which was concordant with clinical response. In the PDOs, depletion or pharmacologic inhibition of NPEPPS increased cisplatin sensitivity, while NPEPPS overexpression conferred resistance. Our data present NPEPPS as a druggable driver of cisplatin resistance by regulating intracellular cisplatin concentrations. Significance: Targeting NPEPPS, which induces cisplatin resistance by controlling intracellular drug concentrations, is a potential strategy to improve patient responses to platinum-based therapies and lower treatment-associated toxicities.

1 January 2022 in Bio-Protocol
Verified
Journal Article
Open access
PDF file
THTanvir Hossain
Tanvir Hossain
SRShahla Romal
Shahla Romal
TMTokameh Mahmoudi
Tokameh Mahmoudi
The absence of long term, primary untransformed in vitro models that support hepatitis B virus (HBV) infection and replication have hampered HBV pre-clinical research, which was reflected in the absence of a curative therapy until recently. One of the limitations for in vitro HBV research has been the absence of high titer and pure recombinant HBV stocks, which, as we describe here, can be generated using simple, and reproducible protocols. In addition to infection of more conventional in vitro and in vivo liver model systems, recombinant high titer purified HBV stocks can also be used to efficiently infect differentiated human liver organoids, whose generation, maintenance, and infection is discussed in detail in a companion organoid protocol. Here, we also describe the protocols for the detection of specific viral read-outs, including HBV DNA in the supernatant of the cultures, covalently closed circular DNA (cccDNA) from intracellular DNA preparations, and HBV viral proteins and viral RNA, which can be detected within the cells, demonstrating the presence of a complete viral replication cycle in infected liver organoids. Although an evolving platform, the human liver organoid model system presents great potential as an exciting new tool to study HBV infection and progression to hepatocellular carcinoma (HCC) in primary cells, when combined with the use of high-titer and pure recombinant HBV stock for infection.Graphical

2 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMathijs Pieter Scholtes
Mathijs Pieter Scholtes
MAMaryam Akbarzadeh
Maryam Akbarzadeh
JNJ. Alberto Nakauma-Gonzales
J. Alberto Nakauma-Gonzales
AGAlexandros Galaras
Alexandros Galaras
ABAmeneh Bazrafshan
Ameneh Bazrafshan
TMTokameh Mahmoudi
Tokameh Mahmoudi
Somatic mutations in ARID1A (AT-rich interactive domain-containing protein 1A) are present in approximately 25% of bladder cancers (BC) and are associated with poor prognosis. With a view to discover effective treatment options for ARID1A-deficient BC patients, we set out to identify targetable effectors dysregulated consequent to ARID1A deficiency. Integrative analyses of ARID1A depletion in normal organoids and data mining in publicly available datasets revealed upregulation of DNA repair and cell cycle-associated genes consequent to loss of ARID1A and identified CHEK1 (Checkpoint kinase 1) and chromosomal passenger complex member BIRC5 (Baculoviral IAP Repeat Containing 5) as therapeutically drug-able candidate molecular effectors. Ex vivo treatment of patient-derived BC tumoroids with clinically advanced small molecule inhibitors targeting CHEK1 or BIRC5 was associated with increased DNA damage signalling and apoptosis, and selectively induced cell death in tumoroids lacking ARID1A protein expression. Thus, integrating public datasets with patient-derived organoid modelling and ex-vivo drug testing can uncover key molecular effectors and mechanisms of oncogenic transformation, potentially leading to novel therapeutic strategies. Our data point to ARID1A protein expression as a suitable candidate biomarker for the selection of BC patients responsive to therapies targeting BIRC5 and CHEK1.

15 May 2024
Verified
Other
Open access
PDF file
RJRobert T. Jones
Robert T. Jones
MSMathijs Scholtes
Mathijs Scholtes
AGAndrew Goodspeed
Andrew Goodspeed
MAMaryam Akbarzadeh
Maryam Akbarzadeh
SMSaswat Mohapatra
Saswat Mohapatra
JCJames Costello
James Costello
Supplementary Figures and Supplementary Table legends.

15 May 2024
Verified
Other
Open access
RJRobert T. Jones
Robert T. Jones
MSMathijs Scholtes
Mathijs Scholtes
AGAndrew Goodspeed
Andrew Goodspeed
MAMaryam Akbarzadeh
Maryam Akbarzadeh
SMSaswat Mohapatra
Saswat Mohapatra
JCJames Costello
James Costello
Supplementary Table from NPEPPS Is a Druggable Driver of Platinum Resistance